Your CREON Connection
This virtual experience provides access to educational presentations,
plus opportunities to connect live with colleagues and
Exocrine Pancreatic Insufficiency (EPI) experts.
Scroll to experience
10+ Years of Experience
as the first pancreatic enzyme replacement
therapy (PERT) to receive FDA approval2
since FDA approval in 20093
Nearly 9 out of 10
GIs prescribe CREON more than other PERTs4
Per Oct '18-Sept '19 analysis of 10,053 GIs, 86% of
surveyed GIs had greater than 50% of their PERT
prescriptions filled as CREON.
coverage for 97%
of patients with the lowest
96% of insured patients
have unrestricted access
(with no prior authorization)4†‡
#1 Prescribed pert5
*“Lowest branded co-pay” means the product is in the formulary tier status designated by the insurer as the lowest branded co-pay in the therapeutic class.
†Rates reflect patients insured through Commercial, Medicare Part D, and Medicaid.
‡Unrestricted access varies by channel: Commercial (98%), Medicare Part D (98%), Fee-for-service Medicaid (92%), Managed Medicaid (85%).
Have questions about EPI or CREON? Now you can connect live for a virtual conversation
led by an expert key opinion leader (KOL). Space is limited so reserve your spot today!
Select a KOL to view available dates and times
Register for Upcoming
Please join us for an AbbVie educational presentation about CREON and EPI.
Register today to reserve your space.
Additional CREON (pancrelipase) Information1
For many adult patients, 36K can be the appropriate strength.
2 capsules with every meal
1 capsule with every snack*
Take during every meal and snack.
CREON efficacy has been studied extensively across various patient populations.
PERTs are not interchangeable.
CREON On Course makes it easy and convenient for patients with EPI to get financial, multivitamin, and educational support.CREON Support
*Patients weighing <160 lb may require a lower lipase unit starting dose. Patients weighing >315 lb may require a higher lipase unit starting dose.